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Objective: Using age-matched controls, this study prospectively evaluated coagu-
lation factor abnormalities and hemodynamic variables in children who had under-
gone the Fontan operation.
Methods: Coagulation factors were assayed in 20 children (mean age 6.4  2.9
years), at a mean 3.7  2.3 years after the Fontan procedure; 24 healthy children
(mean age 6.8 2.8 years) were assayed as controls. Concentration of factors II, V,
VII, VIII, IX, X; ATIII; plasminogen; proteins C and S; fibrinogen; serum albumin;
and liver enzymes were measured. Normal reference intervals based on the control
patients were determined using 95% confidence limits. Patient demographic, hemo-
dynamic variables, and elapsed time after the Fontan procedure were evaluated as
possible predictors of coagulation abnormalities.
Results: Concentrations of protein C; factors II, V, VII, X; plasminogen; and ATIII
were significantly lower in Fontan patients compared with age-matched controls (P
 .01); factor VIII was significantly elevated in 6 patients (35%), 2 of whom had
a thromboembolic event. A higher superior vena cava pressure was predictive of an
elevated factor VIII level (P  .003). No other specific hemodynamic variables
were predictive of a procoagulant or anticoagulant abnormality.
Conclusion: Procoagulant and anticoagulant factor levels were significantly lower in
patients after the Fontan operation independent of hemodynamic variables peculiar
to the Fontan circulation. Increased factor VIII level requires further evaluation as
a cause of thrombosis in patients with Fontan physiology and may also indicate a
subset of these patients in whom anticoagulation is indicated.
Since the original Fontan operation was described, several modifica-tions have been undertaken that have improved early and late mor-bidity and mortality. Survival following the fenestrated lateral tunnelFontan procedure of 93% at 5 years and 91% at 10 years has recentlybeen reported.1 Nevertheless, complications including ventriculardysfunction, thromboembolic events, dysrythmias, and protein losing
enteropathy may compromise longer-term function and outcome.2
The incidence of thromboembolic events in patients with Fontan physiology is
uncertain but has been reported to be as high as 20% to 33%.3-6 Abnormal
coagulation parameters following the Fontan procedure involving both pro- and
anticoagulant factors have been described.7-10 These studies suggested that the
alterations in the coagulation factors found in some Fontan patients are a direct
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consequence of the anatomic and physiologic changes that
result from the Fontan operation. The nature of the “Fontan”
circulation with elevated central venous pressure, low flow
with possible stasis through the atrial baffle and pulmonary
circulation, atrial dysrhythmias, hepatic dysfunction, and
increased resting venous tone are some of the suggested
factors. However, we recently reported that pro- and anti-
coagulant factor abnormalities occur earlier in the course of
staged surgical palliation for single ventricle disease.11,12
Whether this is due to other physiologic derangements such
as cyanosis, low cardiac output, venous congestion, or per-
haps a genetic predisposition is unknown.
Previous studies have evaluated only a small number of
coagulation factor abnormalities after the Fontan operation,
have not used age-matched controls, and have not under-
taken a detailed analysis of hemodynamic variables that
could alter coagulation factor levels. In this single-center,
prospective, cohort study, coagulation factor abnormalities
after the Fontan operation were evaluated, along with he-
modynamic variables peculiar to the Fontan circulation that
could contribute to coagulation abnormalities.
Materials and Methods
After obtaining institutional review board approval and informed
parental consent, 20 children who had undergone a prior Fontan
operation were enrolled in this prospective study. Patients were
excluded if they had preexisting hematological disorders, concur-
rent coagulopathies, or if they were anticoagulated with coumadin;
16 (80%) patients had been receiving aspirin but this was discon-
tinued 7 to 10 days prior to blood draw.
All patients underwent general anesthesia; 13 patients for car-
diac catheterization, 5 patients for permanent pacemaker place-
ment/revision, 1 patient for aortic valvuloplasty, and 1 patient for
elective noncardiac surgery. Blood samples from all patients (8
mL) were obtained from a venous catheter or an indwelling arterial
catheter after induction of general anesthesia. Measured parame-
ters included hemoglobin (Hgb), hematocrit (Hct), platelet count,
prothrombin time (PT), and activated partial prothrombin time
(APTT). Inhibitors of coagulation measured included protein C,
protein S, plasminogen, and antithrombin III; the procoagulant
factors measured were II, V, VII, VIII, IX, X, and fibrinogen.
The Coulter T 660 (Beckman Coulter, Inc, Miami, Fla, USA)
automated hematology analyzer was used to measure Hgb, Hct,
and platelets; coefficients of variation (%) within and between
assays 3 different Hgb levels were: 1.8, 1.0, 0.9; for Hct: 1.8, 1.2,
1.5; and for platelets: 4.8, 2.7, 1.8, respectively.
The ACL 3000 plus (Automated Coagulation Laboratory,
Beckman Coulter Inc, Miami, Fla) was used to assay individual
procoagulant and anticoagulant factors as well as the PT and
APTT. The ACL contains two measuring systems: (1) nephelom-
etry, which is used to detect clot formation as the endpoint, and (2)
photometry, which is used for chromogenic substrate assays.
Blood for these assays was collected in citrated plasma (3.2%
buffered sodium citrate) from an indwelling cannula from which
10 mL of blood had been aspirated to remove residual heparin. The
blood was immediately centrifuged at 13,000 rpm for 5 minutes
and the plasma layer removed. The PT, APTT, and fibrinogen were
measured immediately using nephelometry (coefficients of varia-
tion [%] respectively: PT: 1.2, 2.3; APTT: 2.1, 4.8; fibrinogen: 3.1,
5.5). Remaining plasma was stored at 70°C in 200 L aliquots
for batch performance of the other coagulation assays, as described
below.
Protein C and S activity were both measured using functional
clotting assays. Protein C activity was determined based on the
prolongation of the APTT using the Staclot Protein C kit (Diag-
nostica Stago, Asnieres-Sur-Seine, France) according to the man-
ufacturer’s directions. In this assay, activated protein C inhibits
factor V and VIII activity, thus prolonging the APTT of a system
in which all the factors with the exception of protein C are present
in excess; protein C is derived from the sample being tested
(coefficients of variation [%]: 1.8 and 2.4).
Protein S activity was determined based on the principle of
factor Va inhibition using the Staclot Protein S kit (Diagnostica
Stago, Asnieres-Sur-Seine, France). The principle of the test is
based upon the cofactor activity of protein S, which enhances the
anticoagulant action of activated protein C. This enhancement is
reflected by the prolongation of the clotting time of a system
enriched with factor Va (coefficients of variation [%]: 7.9 and 3.8).
Extrinsic coagulation factors (factors II, V, VII, and X) were
each determined by performing a modified prothrombin time as-
say. Intrinsic coagulation factors (factors VIII and IX) were deter-
mined by performing a modified activated partial thromboplastin
time. In these assays, correction of the clotting time of plasma
specifically deficient in the factor being tested is proportional to
the concentration (activity %) of that factor in the patient plasma,
interpolated from a calibration curve (control plasma deficient in
factors II, V, VII, VIII, IX, or X was obtained from Instrument
Laboratory, Lexington, Mass; coefficient of variation [%] respec-
tively: II: 2.3, 2.7; V: 3.3, 2.3; VII: 2.5, 2.2; VIII: 4.9, 3.7; IX: 3.2,
3.1; X: 3.0, 2.0).
Antithrombin III activity was determined using a synthetic
chromogenic substrate assay that is based upon factor Xa inacti-
vation (Antithrombin III, Instrument Laboratory, Lexington, Mass,
USA; coefficients of variation [%]: 4.3 and 2.8). Plasma plasmin-
ogen was activated through reaction with an excess of streptoki-
nase in the presence of fibrinogen. Plasminogen content was then
determined based on a synthetic chromogenic substrate assay
according to the manufacturer’s directions (Plasminogen, Instru-
ment Laboratory, Lexington, Mass; coefficients of variation [%]:
4.5 and 3.7).
Because altered hepatic dysfunction can contribute to coagula-
tion factor abnormalities, serum alkaline phosphatase, gamma-
glutamyl transferase, alanine transaminase, aspartate transaminase,
total bilirubin, albumin, and total protein were measured in all
patients and compared with normal values for our laboratory.
Age-Matched Control Coagulation Parameters
Coagulation factor levels vary with age and maturation of the
coagulation system, as well as with the reagents used to perform
the different tests. To adjust for this, after informed written paren-
tal consent was obtained, 24 healthy children (9 females, 15
males), mean age 6.8  2.8 years (range 3.0 to 13.5 years),
undergoing minor day surgery procedures were also studied. Blood
was taken from each patient after induction of anesthesia and
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placement of an intravenous catheter and collected into citrated
plasma tubes (3.2% buffered sodium citrate). Blood samples were
immediately centrifuged at 13,000 rpm for 5 minutes and the
plasma stored at 70°C for subsequent batch analyses. Proteins C
and S, plasminogen, fibrinogen, ATIII, and factors II, V, VII, VIII,
IX, X were analyzed as described above.
Potential Hemodynamic Factors
Ventricular morphology (morphologic right or left systemic ven-
tricle), ventricular function, and atrioventricular valve and semi-
lunar valve function were assessed by preoperative echocardiog-
raphy. Superior vena cava O2 saturation (SvO2), the ratio of
pulmonary to systemic blood flow (Qp/Qs), superior vena cava
pressure (SVCp), pulmonary artery pressure (PAP), pulmonary
vascular resistance (PVR), and systemic ventricular end-diastolic
pressure (EDP) were all assessed by cardiac catheterization, either
the day of data collection or within 3 months prior to the proce-
dure. The length of time following the Fontan operation was also
examined as a potential variable contributing to coagulation ab-
normalities.
Statistical Analysis
Normal ranges for each of the 11 coagulation variables and pro-
teins were determined using the empirical 95% confidence inter-
vals. Controls and Fontan patients were compared using the 2-sam-
ple Student t test after testing for normality (Kolmogorov-Smirnov
test). The sample sizes of 24 controls and 20 Fontan patients
provided 85% power (at an  level of 0.05, effect size  1) to
detect a significant difference between the groups for each of the
coagulation factors (version 4.0, nQuery Advisor, Statistical So-
lutions, Boston, Mass). Univariate and multivariate logistic regres-
sion using maximum likelihood estimation was performed to iden-
tify potential predictors of a coagulation abnormality. Variables
evaluated included age, weight, gender, ventricle morphology (left
or right), EDP, SvO2, SVCp, Qp/Qs ratio, PAP, PVR, ventricular
function, atrioventricular valve regurgitation, and time since Fon-
tan operation. Mean coagulation levels in patients with and without
fenestration closure were assessed using Student t tests. Multiple
linear regression was used to develop a prediction equation for
coagulation levels with adjusted R2 as the measure of goodness-
of-fit. Statistical analysis was conducted using the SPSS software
package (version 11.0, SPSS Inc, Chicago, Ill). Values are given as
mean  SD unless otherwise stated. Significance was set at P 
0.05 for 2-tailed comparisons.
Results
The mean age for the 20 patients (3 girls and 17 boys) was
6.4  2.9 years (range 2.6 to 14.5 years) and mean weight
was 19.8  9.8 kg. Patient diagnoses and prior procedures
are summarized in Table 1. Eighteen patients had undergone
a fenestrated intra-atrial lateral tunnel Fontan operation.
Two patients had undergone an extracardiac Fontan opera-
tion, one of which was fenestrated at the time of surgery and
the other fenestrated in the catheterization laboratory be-
cause of protein losing enteropathy (PLE). Three patients
(15%) had signs of PLE with hypoproteinemia and ascites;
2 of these patients had elevated SVCp (20 and 20 mm Hg)
and EDP (12 and 14 mm Hg), respectively. The follow-up
period between the Fontan operation and inclusion in our
study was 3.7  2.3 years (range 8.5 months to 9.5 years).
Thirteen patients had a morphologic right ventricle and 7
had a morphologic left ventricle. There were no differences
in measured hemodynamics based on ventricular morphol-
ogy. Hemodynamic variables as assessed either by echocar-
diography or cardiac catheterization are shown in Table 2.
Normal Ranges
For the 24 control subjects (9 girls, 15 boys), the mean age
was 6.8  2.8 years (range 3.5 to 13.5 years). The normal
reference ranges for coagulation factors are shown in Table
3. Normal ranges were based on the empirical 95% confi-
dence intervals derived from the 2.5 and 97.5 percentile
confidence limits.
Coagulation Abnormalities
The comparison between coagulation factors in Fontan pa-
tients and healthy controls is summarized in Table 4. Sig-
nificant reductions in the levels of both procoagulant factors
and inhibitors of coagulation were detected in all 20 Fontan
patients. Concentration of protein C; factors II, V, VII, X;
plasminogen; and ATIII were significant lower in Fontan
patients compared with age-matched controls (P  .01).
Using univariate and multivariate logistic regression, no
significant relationship between these coagulation abnor-
malities and gender, weight, prior procedure, serum albu-
TABLE 1. Cardiac diagnoses of patients after the Fontan
procedure
Diagnoses n Prior surgery
Morphologic LV
DILV/MA 1 BTS, BDG, FenFon
DILV 1 PAB, BDG, FenFon
DILV/TGA 3 1 St1, FenFon, PPM/1 BDG, PPM, FenFon/1
BDG, Ex.FenFon
TA/PS 1 BTS, FenFon
TGA/PA 1 BTS, FenFon
Morphologic RV
DORV/VSD 2 1 PAB, BDG, FenFon/1 PAB, FenFon
DORV/MA 1 PAB, BDG, FenFon
DORV/PS/MS 1 BDG, FenFon
TA/PS 1 BTS, FenFon
TGA/PA 1 BTS, FenFon
HLHS 8 8 St1, BDG/7, FenFon/1 Ex. FenFon/1 PPM
Heterotaxy 1 BTS, BDG, FenFon
BDG, Bidirect Glenn procedure; BTS, Blalock-Taussig shunt; DILV, double
inlet left ventricle; DORV, double outlet right ventricle; FenFon, Fenestrated
Fontan procedure; Ex.FenFon, extracardiac fenestrated Fontan procedure;
HLHS, hypoplastic left heart syndrome; MA, mitral stenosis; MS, mitral
stenosis; PA, pulmonary atresia; PAB, pulmonary artery band; PPM, per-
manent pacemaker; PS, pulmonary stenosis; St1, stage 1 procedure (Nor-
wood); TA, tricuspid atresia; TGA, transposition of great arteries; VSD,
ventricular septal defect.
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min, the hemodynamic variables previously listed (diagno-
sis, right or left ventricle morphology, ventricular function,
AVVR, PVR, oxygen saturation, SVO2, Qp/Qr ratio, PO2,
SVCp, transpulmonary gradient, and EDP) or the time pe-
riod after the Fontan procedure could be identified (all P 
.20).
In contrast, factor VIII was significantly elevated in
Fontan patients compared with controls (P .04; Figure 1).
Six patients (35%) had markedly elevated factor VIII levels
(150% activity) compared with the controls. Multiple
linear regression analysis indicated that SVCp was a strong
predictor of factor VIII levels and this relationship was
maintained after controlling for all other hemodynamic and
laboratory variables (adjusted R2  0.74, P  .003). The
relationship between SVCp and factor VIII is illustrated in
Figure 2. The predictive equation derived from this model
was: Factor VIII (%)  12.7  SVCp  28.
No significant correlations were detected between time
since the Fontan operation and any of the 11 coagulation
factors or proteins (all P  .2).
Hemostatic Variables and Liver Function
The mean Hct, platelet count, PT, APTT, and liver function
tests (LFTs) for Fontan patients are shown in Table 5.
Partial thromboplastin time (PTT) was abnormally elevated
in 29% of the patients. In all but three patients, abnormal PT
and/or PTT values corrected when calibration plasma (In-
strumentation Laboratory Company, Lexington, Mass) was
added in a 50:50 ratio to patient’s plasma. Calibration
plasma is obtained from healthy donors and is processed to
maintain the characteristics of normal plasma. Normaliza-
tion by calibration plasma indicates one or more factor
deficiencies as the cause of the PT or PTT prolongation (as
opposed to circulating anticoagulants such as heparin).
Three patients did not normalize with calibration plasma for
PTT, which was interpreted as heparin contamination; these
patients were excluded from PTT evaluation. Three patients
failed to normalize with calibration plasma; because protein
C and factor VIII and IX assays are also based upon pro-
longation of the PTT, their protein C and factor VIII and
factor IX data were excluded from analysis.
Liver function tests are also shown in Table 5. Several
patients had small elevations of aspartate aminotransferase
and alanine aminotransferase, but mean values were within
the normal range; gammaglutamyl transpeptidase was ele-
vated in 9 patients (45%), and 5 patients (25%) had signs of
hypoproteinemia (albumin 3 g/dL), including the 3 pa-
tients who carried the clinical diagnosis of PLE. There were
no correlations between abnormal liver function tests, he-
modynamic variables such as elevated SVCp, or coagula-
tion factor abnormalities.
Thromboembolic Events
Two patients in our series had a history of significant
thromboembolic events. Factor VIII levels for these 2 pa-
tients were significantly higher than the other 15 patients
(239  30% versus 116  58%, respectively, P  .01,
Student t test). One 5-year-old male with PLE was admitted
with severe ventricular dysfunction 2.5 years after his Fon-
tan operation. Thrombus in his common atrium and superior
vena cava was detected. He was ultimately placed on ex-
tracorporeal membrane oxygenation for low cardiac output
state and underwent successful orthotopic cardiac trans-
plant. This patient’s coagulation profile measured 5 months
prior to the event mentioned above was significant for a low
normal protein S level, elevated factor V and IX levels
TABLE 3. Normal ranges for coagulation factors and pro-
tein levels
Variable Median Mean  SD Normal range*
Fibrinogen (mg/L) 321 315 107 104-570
Factor II (%) 92 97 17 71-130
Factor V (%) 107 106 23 76-160
Factor VII (%) 92 97 24 67-172
Factor VIII (%) 99 98 25 43-143
Factor IX (%) 78 81 22 52-136
Factor X (%) 91 94 17 66-126
Antithrombin III (%) 109 107 16 50-127
Plasminogen (%) 102 100 14 77-134
Protein C (%) 97 98 23 56-147
Protein S (%) 83 87 17 69-133
*Normal ranges were based on the empirical 95% confidence intervals
derived from the 2.5 and 97.5 percentile limits (n  24), except fibrinogen
(n  21). SD, Standard deviation.




Mildly depressed 5 (26%)
Moderately severely depressed 1 (5%)
AVVR
No regurgitation 4 (21%)
Trivial 3 (16%)
Mild–moderate 12 (63%)
EDP (mean mm Hg) 8.2 3.7
SVCp (mean mm Hg) 12.9 4.3
TPG (mean mm Hg) 5.4 1.7
PVR (Wood units) 1.9 0.6
Qp/Qs 0.85 0.2
PaO2 mm Hg 59.5 8.2
SvO2 (%) 66 0.1
SpO2 (%) 88 0.1
Data expressed as number (%), and mean  standard deviation. AVVR,
Atrioventricular valve regurgitation; CVP, superior vena cava pressure;
EDP, end-diastolic pressure; PAP, pulmonary artery pressure; PO2, oxygen
tension; PVR, pulmonary vascular resistance; Qp/Qs, pulmonary to sys-
temic blood flow; SpO2, oxygen saturation; SvO2, superior vena cava O2
saturation; TPG, transpulmonary gradient.
Odegard et al Surgery for Congenital Heart Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 6 1263
CH
D
(138% and 132%, respectively), and a markedly elevated
factor VIII level of 260%. LFTs were within normal levels
except an albumin level of 1.2 g/dL.
The second patient was a 8-year-old boy who had pre-
viously undergone an extracardiac nonfenestrated Fontan
procedure. He developed progressive PLE and ascites and
was admitted for creation of a fenestration in the Fontan
baffle. Within hours of the procedure the fenestration be-
came obstructed by thrombus and he was treated with
fibrinolytic agents and heparin. He was subsequently dis-
charged home on coumadin. This patient’s coagulation pro-
file on the morning of the procedure (prior to thrombus
formation) revealed a normal PT, APTT, and protein C and
S levels but markedly elevated factor VIII level (218%) and
elevated factor IX (125%). LFTs were within normal levels
with an albumin of 2.1 g/dL.
No other patients demonstrated clinical evidence of
thromboembolic events, and no intracardiac thrombus was
detected by transthoracic echocardiography. The majority
of the patients (16/20) were discharged home on aspirin
alone; 1 patient was discharged on Coumadin; and 3 pa-
tients were not given any antiplatelet or anticoagulant ther-
apy.
Discussion
In this prospective study of coagulation profiles in children
with complex single ventricle congenital heart disease who
had undergone a prior Fontan operation, abnormalities of










Fibrinogen (mg/L) 315 107 254 74 .05 0 (0) 0 (0)
Factor II (%) 97 17 72 10 .01 8 (40) 0 (0)
Factor V (%) 106 23 72 28 .01 10 (50) 0 (0)
Factor VII (%) 97 24 53 19 .01 17 (85) 0 (0)
Factor VIII (%) 98 25 131 68 .04 0 (0) 6 (35)
Factor IX (%) 81 21 72 31 .28 4 (24) 0 (0)
Factor X (%) 94 17 73 15 .01 5 (25) 0 (0)
Antithrombin III (%) 107 16 84 24 .01 2 (10) 1 (5)
Plasminogen (%) 100 14 83 18 .01 6 (30) 0 (0)
Protein C (%) 98 22 66 15 .01 3 (18) 0 (0)
Protein S (%) 87 17 80 14 .17 4 (22) 0 (0)
*P values were determined by the 2-sample Student t test. All variables are expressed in terms of the mean SD. n 24 for controls, except for fibrinogen
(n  21); n  20 for Fontan patients except for factor VIII, factor IX, and protein C (n  17) and for protein S (n  18).
Figure 1. Factor VIII activity in Fontan patients and age-matched controls. Mean factor VIII levels were signifi-
cantly higher in patients than controls (131  68% versus 98  25%, P  .04. Asterisks (*) indicate the 2 patients
who clotted. The mean factor VIII level for each group is marked by a small horizontal bar.
Surgery for Congenital Heart Disease Odegard et al
1264 The Journal of Thoracic and Cardiovascular Surgery ● June 2003
CH
D
procoagulant factors and inhibitors of coagulation were
demonstrated in all children. Although there was no corre-
lation between the significantly low levels of various factors
with hemodynamic variables or liver function tests, the
significant elevation in factor VIII, and its correlation with
an increased SVC pressure, could suggest a prothrombotic
relationship in patients with Fontan physiology.
The cause of thromboembolic events after the Fontan
procedure seems to be multifactorial, and no consistent
predisposing risk factors have been identified. Several au-
thors have previously described coagulation factor abnor-
malities involving both pro- and anticoagulant proteins as a
cause of a hypercoagulable state in children who have
previously undergone the Fontan operation, with specific
emphasis on low levels of the naturally occurring inhibitors
of coagulation, protein C, protein S and, ATIII.7-10 These
earlier studies suggested that an imbalance between proco-
agulant factors and inhibitors of coagulation favors throm-
bus formation and that one or more aspects of the Fontan
physiology may be responsible for the imbalance. However,
these studies did not examine a full complement of coagu-
lation factors and did not employ age-matched control sub-
jects, nor did they undertake detailed hemodynamic evalu-
ation.
The use of age-matched controls is important because the
hemostatic system matures over the first several years of
life,13 leading to important differences in factor activity
measurements in children compared with adults. In general,
values of most pro- and anticoagulant factors are lowest in
neonates and infants and increase toward adult values at
Figure 2. Scatter diagram of the empirical data showing the positive correlation between factor VIII activity as a
function of SVC pressure in Fontan patients. The fitted model showed a good linear fit (R2 0.74) for the regression
equation: y  12.7x  28 (solid line).
TABLE 5. Laboratory values for Fontan patients
Variable n Mean  SD Normal range
Number (%) above or
below normal range
Hematocrit (%) 19 39 5 33-55 2 (11)
Platelet count (103) 19 221 59 130-400 1 (5)
PT (seconds) 19 12.9 1.4 11-13 6 (32)
PTT (seconds) 17 38.6 22 27-37 5 (29)
Albumin (g/dL) 20 3.2 0.7 3.0-4.6 5 (25)
AST (U/L) 20 38 11 2-40 9 (45)
ALT (U/L) 20 24 12 0-35 2 (10)
GGTP (U/L) 19 46 30 5-40 9 (47)
Bilirubin (mmol/L) 20 0.8 0.7 0.3-1.2 1 (5)
SD, Standard deviation; PT, prothrombin time; PPT, partial thromboplastin time; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGTP,
gammaglutamyl transpepsidase.
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varying rates, some not reaching adult levels until relatively
late in the teenage years. Despite the observed differences
there is no evidence that infants are at greater risk for hemor-
rhagic or thrombotic problems compared with adults, suggest-
ing that the neonatal and infant system is in “functional
balance” at lower concentrations of most factors. Whether
the overall coagulation factor abnormalities (compared to
age-matched controls) we measured in our patients are due
to delayed maturation in the Fontan patient is speculative.
Hepatic synthetic dysfunction (eg, reduced albumin) or
evidence of hepatocellular dysfunction (eg, bilirubin,
transaminase) did not appear to be associated with coagu-
lation abnormalities in our patients, an important observa-
tion given the prominent role of the liver in the synthesis of
procoagulants and inhibitors of coagulation and the poten-
tial for altered liver blood flow and oxygen delivery in
Fontan patients. We were unable to relate specific hemody-
namic variables, including an elevated SVCp or poor ven-
tricular function, with altered hepatic synthetic function.
We have previously reported that abnormalities in coag-
ulation factor levels may occur earlier in the staged pallia-
tion of complex single ventricle disease.11,12 The changes
after the Fontan procedure found in our present study are
qualitatively and quantitatively similar to those found in pa-
tients prior to the Fontan operation, with the important excep-
tion of factor VIII. In contrast to the two prior stages of single
ventricle repair (pre-Glenn and pre-Fontan) where factor VIII
concentrations were lower than age-matched controls, it ap-
pears that Fontan physiology is associated with a specific
tendency to increase factor VIII; in 6 patients the level was
significantly above the normal range. A similar finding was
recently reported by Rauch and colleagues in 20 patients 4 to
63 months following the total cavopulmonary connection.14
The importance of an elevated factor VIII level as an
independent risk factor for venous thrombosis in patients
without cardiac defects has been reported.15-19 Factor VIII
levels 150% are associated with a five- to sixfold in-
creased risk for venous thrombosis when compared with
levels below 100%.20 The overall prevalence of an elevated
factor VIII appears to be relatively high, having been re-
ported in one study to be elevated in 25% of patients with a
first episode of venous thrombosis and 11% of the healthy
population.18 In a prospective study by Kyrle and col-
leagues of 360 adult patients, the risk of recurrence of
thromboembolism was almost 7 times as great among pa-
tients with factor VIII levels above the 90th percentile
(234%),15 and it was speculated that prolonged anticoag-
ulation therapy may be indicated in this subset of patients.
The cause of increased factor VIII levels in patients with
Fontan circulation is unknown. The apparent conversion
from a state of relatively low factor VIII earlier in the course
of single ventricle repair suggests an acquired disturbance
related directly to Fontan physiology. This is supported in
our study by the significant relationship demonstrated be-
tween factor VIII activity and the higher SVC pressure.
Factor VIII is expressed by multiple tissues. A recent report
by Hollestelle and colleagues21 showed that the liver and
kidney especially express high levels of factor VIII mRNA
compared with the level of expression of other hemostatic
proteins in these organs. Further analysis indicated that
most of the VIII mRNA expression was detected in the
endothelial lining of the liver sinusoids; a significantly
lower signal was detected in hepatocytes. Although specu-
lative, it is possible that the Fontan circulation with elevated
central and hepatic venous pressure may contribute to an
increase in factor VIII production from liver sinusoidal
endothelium. This could also explain the lower factor VIII
levels detected in patients with bidirectional Glenn physi-
ology who have lower atrial and hepatic venous pressure.
In view of the potential risk of thromboembolic events in
post-Fontan patients and evidence that high levels of factor
VIII may be an independent risk factor for both early and
late thromboembolic events, quantifying factor VIII may
identify a subset of Fontan patients who would benefit from
anticoagulant treatment. Further work is clearly necessary
to determine whether there may be a critical factor VIII
plasma concentration associated with thromboembolic risk
in these patients and also whether, analogous to adult venous
thrombosis events, there is an interaction with low levels of
native circulating inhibitors of coagulation (eg, proteins C
and S and ATIII) or prothrombotic genetic mutations.
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